Culturally adapted therapies for early psychosis in Pakistan
Official title: Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting: a Large Multi-center Randomised Controlled Trial
Run by Pakistan Institute of Living and Learning · NCT05814913 · Data updated 2026-11-12
This study is testing if specially adapted therapy programs can help people in Pakistan who are experiencing their first episode of psychosis feel better compared to standard treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 390 (estimated) |
| Sponsor | Pakistan Institute of Living and Learning Academic / other |
| Locations | 1 site (Karachi, Sindh) |
| Status | Recruiting |
| Started | April 15, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | December 12, 2024 |
| Trial ID | NCT05814913 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals over 18 years old with a confirmed diagnosis of schizophrenia or related disorders, experiencing their first episode of psychosis, and who have a supportive carer willing to participate.
✕Probably not a fit
Patients with active substance use disorders or severe cognitive disorganization may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) in reducing symptoms of psychosis in individuals experiencing their first episode of psychosis in Pakistan. The study will involve 390 participants who will be randomly assigned to receive either CaCBT, CulFI, or Treatment As Usual (TAU). Participants will undergo a series of therapy sessions delivered by trained psychologists, with assessments conducted at multiple time points to measure outcomes related to psychosis symptoms, quality of life, and caregiver wellbeing. The study also seeks to assess the economic impact of these interventions in a low-resource setting.
Why it matters
Potential benefit: If successful, this study could provide effective, culturally tailored interventions for individuals with early psychosis, improving their symptoms and overall quality of life.
How similar studies have gone: While there is limited evidence from low- and middle-income countries regarding the efficacy of these culturally adapted interventions, similar approaches have shown promise in other settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for patient participants: * Individuals of all genders aged over 18 years; diagnosis of schizophrenia confirmed by Structured Clinical Interview for DSM (SCID) meeting DSM-5 criteria for schizophrenia, schizophreniform or schizoaffective psychosis * Scored at least 4 on the PANSS delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items * stable on medication for the past four weeks * in contact with mental health services * within 3 years of diagnosis * able to demonstrate the capacity to provide informed consent to take part in the study * potential participants must have a carer or relative who is also willing to participate in the study to be eligible Exclusion Criteria for patient participants: * Active DSM-5 substance use disorder (except nicotine or caffeine) or dependence within the last three months * A score of 5 or more on the PANSS conceptual disorganisation item * Individuals who have received structured psychological intervention within the past 3 months * Relevant CNS or other medical disorders that would impact participation * Diagnosis of intellectual disability * Unstable residential arrangements Family member/Carer participant inclusion criteria: * Living with or spending at least 10 hours per week in face-to-face contact with an individual with early psychosis and assuming a caring role * Age\>18 years * Able to give informed written consent. Family member/Carer participant exclusion criteria: * Active DSM-5 substance use disorder * Received psychological intervention within the past 3 months * Unstable residential arrangements.
Where it's running
-
Civil hospital
Karachi, Sindh, Pakistan Recruiting
Study contacts
- Principal investigator: Omair Husain, MD — Centre for Addiction and Mental Health
- Study coordinator: Ameer B Khoso
- Email: ameer.bukhsh@pill.org.pk
- Phone: 021-35371084
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
State Representation in Early Psychosis 2
This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.
-
Recovery-oriented suicide prevention for young people at clinical high risk for psychosis
This program tests a peer-supported, clinician-led suicide prevention group for young people at clinical high risk for psychosis to see if it helps reduce suicidal thoughts and support recovery.
-
Combined brain stimulation and yoga for improving cognition in psychosis
This study tests whether active brain stimulation plus yoga can improve thinking skills and daily function in adults with psychosis.
-
See if an early-detection program reduces time to treatment for first-episode psychosis
We test whether a large, region-wide early-detection program can shorten the time from first psychotic symptoms to treatment and help people function better later.
-
Cerebellar imaging markers to predict antipsychotic response in first-episode psychosis
This will test whether cerebellar brain scans can predict how people with first-episode psychosis respond to 12 weeks of treatment with risperidone or aripiprazole.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.